Literature DB >> 18277079

A promoter polymorphism of the alpha 8 integrin gene and the progression of autosomal-dominant polycystic kidney disease.

Raoul Zeltner1, Karl F Hilgers, Roland E Schmieder, Markus Porst, Bernd D Schulze, Andrea Hartner.   

Abstract

BACKGROUND/AIMS: Dysregulation of integrins is a feature of tissue remodeling in autosomal-dominant polycystic kidney disease (ADPKD). The alpha 8 beta 1 integrin (alpha8beta1) affects kidney development and the susceptibility to renal injury in mice. We investigated whether the -414 T/C polymorphism in the promoter region of the alpha 8 integrin chain gene (ITGA8) is associated with the progression of renal disease in ADPKD.
METHODS: Genotyping for the -414 T/C polymorphism was performed by allelic separation using RT-PCR in 294 patients with ADPKD. Alpha 8 integrin expression was detected by RT-PCR and immunohistochemistry.
RESULTS: 41% of the study population reached end stage renal disease at a mean age of 51 +/- 12 years. The frequency of the -414 C allele was 0.194 in ADPKD. C allele carriers (CC and TC genotypes) were compared with patients homozygous for the T allele (TT genotype). Kaplan-Meier analysis revealed that end-stage renal failure occurred at a significantly younger age in TT homozygotes (median age, 47 years; 95% CI, 46-49 years) than in C allele carriers (median age, 51 years; 95% CI, 49-53 years; p = 0.046 by the log-rank test). When parameters of ADPKD patients were compared between genotype by analysis of variance, only age at onset of end-stage renal failure was significantly different (p = 0.026) whereas age at onset of hypertension, body surface area, 24-hour systolic and diastolic blood pressure did not differ. In kidneys of ADPKD, expression of alpha 8 integrin is increased and found de novo in cystic epithelia.
CONCLUSION: A polymorphism of the ITGA8 promoter modifies the progression of renal failure in ADPKD. Copyright 2008 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18277079     DOI: 10.1159/000116887

Source DB:  PubMed          Journal:  Nephron Clin Pract        ISSN: 1660-2110


  10 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 2.  Fibrosis and progression of autosomal dominant polycystic kidney disease (ADPKD).

Authors:  Jill Norman
Journal:  Biochim Biophys Acta       Date:  2011-07-01

Review 3.  Predictors of autosomal dominant polycystic kidney disease progression.

Authors:  Robert W Schrier; Godela Brosnahan; Melissa A Cadnapaphornchai; Michel Chonchol; Keith Friend; Berenice Gitomer; Sandro Rossetti
Journal:  J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 10.121

4.  Integrin-Linked Kinase Signaling Promotes Cyst Growth and Fibrosis in Polycystic Kidney Disease.

Authors:  Archana Raman; Gail A Reif; Yuqiao Dai; Aditi Khanna; Xiaogang Li; Lindsay Astleford; Stephen C Parnell; James P Calvet; Darren P Wallace
Journal:  J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 10.121

Review 5.  Extracellular matrix, integrins, and focal adhesion signaling in polycystic kidney disease.

Authors:  Yan Zhang; Gail Reif; Darren P Wallace
Journal:  Cell Signal       Date:  2020-04-18       Impact factor: 4.315

6.  Multiomic identification of factors associated with progression to cystic kidney disease in mice with nephron Ift88 disruption.

Authors:  Chunyan Hu; Katherine Beebe; Edgar J Hernandez; Jose M Lazaro-Guevara; Monica P Revelo; Yufeng Huang; J Alan Maschek; James E Cox; Donald E Kohan
Journal:  Am J Physiol Renal Physiol       Date:  2021-12-20

7.  Total Glucosides of Paeony Alleviate Cell Apoptosis and Inflammation by Targeting the Long Noncoding RNA XIST/MicroRNA-124-3p/ITGB1 Axis in Renal Ischemia/Reperfusion Injury.

Authors:  Fang Chen; Yi Hu; Yuetao Xie; Zonghui Zhao; Lin Ma; Zhili Li; Wanlong Tan
Journal:  Mediators Inflamm       Date:  2020-11-24       Impact factor: 4.711

Review 8.  Integrins in kidney disease.

Authors:  Ambra Pozzi; Roy Zent
Journal:  J Am Soc Nephrol       Date:  2013-05-02       Impact factor: 10.121

9.  Tubulointerstitial de novo expression of the α8 integrin chain in a rodent model of renal fibrosis--a potential target for anti-fibrotic therapy?

Authors:  Andrea Hartner; Carlos Menendez-Castro; Nada Cordasic; Ines Marek; Gudrun Volkert; Bernd Klanke; Wolfgang Rascher; Karl F Hilgers
Journal:  PLoS One       Date:  2012-11-08       Impact factor: 3.240

10.  Tadalafil monotherapy in management of chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial.

Authors:  Ahmed M Tawfik; Mohammed H Radwan; Mohammed Abdulmonem; Mohammed Abo-Elenen; Samir A Elgamal; Mohammed O Aboufarha
Journal:  World J Urol       Date:  2022-07-08       Impact factor: 3.661

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.